Meta Acquires AI Startup Manus to Expand Advanced AI Capabilities Across Platforms 
Trump Administration Probes Corporate DEI Programs, Raising Questions for Google Stock 
BP’s Castrol Stake Sale Raises Debt Relief Hopes but Sparks Cash Flow Concerns 
Sanofi to Acquire Dynavax in $2.2 Billion Deal to Strengthen Vaccine Portfolio 
Boeing Secures $8.6 Billion Pentagon Contract for F-15 Jets for Israel 
China’s LandSpace Takes Aim at SpaceX With Reusable Rocket Ambitions 
Warner Bros. Discovery Shares Slide Amid Report of Potential Paramount Skydance Lawsuit 
California DMV Proposes New Safety Rules for Autonomous Vehicles After Waymo Incidents 
Novo Nordisk and Eli Lilly Cut Obesity Drug Prices in China, Boosting Access to Wegovy and Mounjaro 
Applied Digital Stock Rises on AI Cloud Spinoff Plan and ChronoScale Launch 
Samsung Electronics Secures Annual U.S. Licence for China Chip Equipment Imports in 2026 
Boeing Secures Multi-Billion Dollar Defense Contracts for F-15IA Jets and E-4B Aircraft Support 
Royalty Pharma Stock Rises After Acquiring Full Evrysdi Royalty Rights from PTC Therapeutics 
Hyundai Recalls Over 51,000 Vehicles in the U.S. Due to Fire Risk From Trailer Wiring Issue 
Leapmotor Targets 4 Million Annual EV Sales as Global Expansion Accelerates 
Australia’s Modern Gold Rush: Hobby Prospectors Flock to Victoria’s Golden Triangle 
 & Lead Plaintiff Deadline: November 29, 2016 - EconoTimes)
NEW YORK, Nov. 22, 2016 -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed against Seres Therapeutics, Inc. (“Seres” or the “Company”) (Nasdaq:MCRB) and certain of its officers, on behalf of shareholders who held Seres securities between June 25, 2015 and July 29, 2016.
This class action seeks to recover damages against Defendants for alleged violations of the federal securities laws under the Securities Exchange Act of 1934 (the “Exchange Act”).
The complaint alleges that throughout the Class Period, Seres made materially false and misleading statements regarding the potential and efficacy of the Company’s lead drug product candidate SER-109. Specifically, the complaint alleges that Seres advertised and hyped the drug as “novel class of biological drugs” and a potential “first-in-field drug” despite knowledge that the Phase 2 clinical trial of SER-109 would fail to achieve its primary endpoint as compared to placebo.
On July 29, 2016, Seres announced that the Phase 2 clinical trial of SER-109 did not reach its primary endpoint. President and CEO Roger J. Pomerantz in an earnings call also admitted that certain undisclosed modifications had been made to SER-109 formulation before the trial. Following this news, Seres Therapeutics stock dropped from a close of $35.77 per share on July 28, 2016, to a close of just $9.73 on August 1, 2016.
A class action lawsuit has already been filed. If you wish to review a copy of the Complaint you can visit the firm’s site: http://www.bgandg.com/mcrb or you may contact Peretz Bronstein, Esq. or his Investor Relations Analyst, Yael Hurwitz of Bronstein, Gewirtz & Grossman, LLC at 212-697-6484 or via email [email protected]. Those who inquire by e-mail are encouraged to include their mailing address and telephone number. If you suffered a loss in Seres you have until November 29, 2016 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.
Bronstein, Gewirtz & Grossman, LLC is a corporate litigation boutique. Our primary expertise is the aggressive pursuit of litigation claims on behalf of our clients. In addition to representing institutions and other investor plaintiffs in class action security litigation, the firm’s expertise includes general corporate and commercial litigation, as well as securities arbitration. Attorney advertising. Prior results do not guarantee similar outcomes.
Contact: Bronstein, Gewirtz & Grossman, LLC Peretz Bronstein or Yael Hurwitz 212-697-6484 | [email protected]
